Have any questions? 706-721-6582 or cts@augusta.edu
- Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment with NLY01 in Early-stage Parkinson’s Disease
Clinical Trial
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment with NLY01 in Early-stage Parkinson’s Disease
This research is studying a new experimental drug, NLY01, in a large number of persons to learn about its effects in people with early Parkinsons disease. Researchers want to know whether NLY01 helps lessen symptoms and signs of early Parkinsons disease and whether it slows the progression of Parkinson?s disease. .
Eligibility Criteria
- Has been diagnosis with Parkinsons Disease PD Patient is 30 to 80 years old
RESEARCH. INNOVATION. DISCOVERY.